BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
» Moderna to file for EUA of mRNA-1273 for COVID-19 following primary efficacy analysis
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Moderna to file for EUA of mRNA-1273 for COVID-19 following primary efficacy analysis
Nov. 30, 2020
No Comments
Moderna has announced that the primary efficacy analysis of the phase III COVE study of
mRNA-1273
conducted on 196 cases has confirmed the high efficacy observed at the first interim analysis (
ClinicalTrials.gov Identifier NCT04470427
).
Science
Vaccines
Coronavirus